Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26897012 | 0.82 | ACHE (0.35) | ACHEEPHB4TEK | |
| SCHEMBL2611113 | 0.81 | NPBWR1 (0.41) | NPBWR1LRRK2EPHB4TEKPDK2 | |
| SCHEMBL21536772 | 0.78 | ALOX5AP (0.33) | AXL | |
| SCHEMBL26858663 | 0.77 | KCNH2 (0.35) | NPBWR1LRRK2EPHB4TEKPDK2 | |
| SCHEMBL23136075 | 0.76 | ACHE (0.36) | ACHEPDK2 | |
| SCHEMBL26859844 | 0.72 | TEK (0.33) | NPBWR1LRRK2EPHB4TEKPDK2 | |
| SCHEMBL179481 | 0.72 | KDM5B (0.33) | — | |
| SCHEMBL31595940 | 0.71 | ERN1 (0.36) | NPBWR1LRRK2EPHB4TEKPDK2 | |
| SCHEMBL26897003 | 0.71 | GRN (0.30) | — | |
| SCHEMBL28035651 | 0.70 | ALDH1A1 (0.32) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224998-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2021237121-A1 | SUBSTITUTED PYRIDINES | GOSSAMER BIO SERVICES, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374022-A1 | INHIBITORS OF PARG | PARG, PLG, SERPINB1 | ACHE 1254/4885OGA 2272/4885NPBWR1 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.